

2025 ASCO[®] ANNUAL MEETING



Dra. Nieves Martínez Lago

Servicio de Oncología Médica. Hospital Clínico Universitario de Santiago de Compostela - Santiago de Compostela (A Coruña)

TITULARES EN CÁNCER ESOFAGOGÁSTRICO ENFERMEDAD LOCALMENTE AVANZADA

Resumen en vídeo

Resumen en texto

MATTERHORN

LBA 5. Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).

Ver Abstract

CheckMate 577

4000. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.

Ver Abstract

ESOPEC

4014. Recurrence patterns in the prospective, randomized, controlled, multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma.

Ver Abstract



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS

2025 ASCO[®] ANNUAL MEETING



Dra. Nieves Martínez Lago

Servicio de Oncología Médica. Hospital Clínico Universitario de Santiago de Compostela - Santiago de Compostela (A Coruña)

TITULARES EN CÁNCER ESOFAGOGÁSTRICO ENFERMEDAD METASTÁSICA HER2 POSITIVA

Resumen en vídeo

Resumen en texto

DESTINY-Gastric04

LBA 4002. Trastuzumab deruxtecan (T-DXd) vs. ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.

Ver Abstract

Abstract 4013

4013. Long-term outcomes and overall survival for zanidatamab + chemotherapy in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma: 4-years follow-up of a phase II.

Ver Abstract



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS

2025 ASCO[®] ANNUAL MEETING



Dra. Nieves Martínez Lago

Servicio de Oncología Médica. Hospital Clínico Universitario de Santiago de Compostela - Santiago de Compostela (A Coruña)

TITULARES EN CÁNCER ESOFAGOGÁSTRICO ENFERMEDAD METASTÁSICA HER2 NEGATIVA

Resumen en vídeo

Resumen en texto

LEAP-015

4001. Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.

Ver Abstract

CT041-ST-01

4003. Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).

Ver Abstract



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS